Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05307705 · ClinicalTrials.gov registry record · Phase 1

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

A Phase 1 study of Breast Cancer, sponsored by Eli Lilly and Company.

Active
Registry status
Phase 1
Development phase
193
Enrollment target
20
Study locations

NCT05307705 is a Phase 1 study of Breast Cancer that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 193 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05307705, a Phase 1 study of Breast Cancer, is active but no longer recruiting, sponsored by Eli Lilly and Company.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
193 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and possibly longer if the disease does not get worse.

Conditions Studied

Breast Cancer

Interventions

  • DRUG Fulvestrant
  • DRUG Abemaciclib
  • DRUG Imlunestrant
  • DRUG LOXO-783
  • DRUG Anastrozole, Exemestane, or Letrozole

Study Locations (20)

Texas

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center - Dallas
  • UT Southwestern Medical Center - Dallas
  • University of Texas MD Anderson Cancer Center - Houston
  • South Texas Accelerated Research Therapeutics (START) - San Antonio

California

  • UCLA Medical Center - Los Angeles
  • UCSF Medical Center at Mission Bay - San Francisco
  • Stanford University Hospital - Stanford

Other

  • Cancer Research SA - Adelaide
  • Peter Maccallum Cancer Institute Erb - East Melbourne
  • St Vincent's Hospital - Sydney

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

New York

  • Memorial Sloan Kettering Cancer Center - New York
  • Wilmot Cancer Institute - Rochester

Arizona

  • Mayo Clinic of Scottsdale - Scottsdale

Florida

  • Mayo Clinic - Jacksonville

Georgia

  • Winship Cancer Center Emory University - Atlanta

Trial Details

FieldValue
Enrollment Target 193 participants
Start Date 2022-05-11
Est. Completion 2026-12
Phase Phase 1

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05307705

The ClinicalTrials.gov registry entry for NCT05307705 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 193 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Fulvestrant is the first listed.

NCT05307705 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Texas, California, Other.

Frequently Asked Questions

What is clinical trial NCT05307705 about?

NCT05307705 is a clinical study titled "A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors". The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and...

What is the current status of trial NCT05307705?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 193 participants. The study started on 2022-05-11. Estimated completion is 2026-12.

What conditions does trial NCT05307705 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT05307705?

The interventions under investigation include: Fulvestrant (DRUG), Abemaciclib (DRUG), Imlunestrant (DRUG), LOXO-783 (DRUG), Anastrozole, Exemestane, or Letrozole (DRUG).

Who is sponsoring clinical trial NCT05307705?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05307705 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.